Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Larkspur Biosciences, Inc.

Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
From Larkspur Biosciences, Inc.
Via GlobeNewswire
Larkspur Biosciences to Present New Preclinical Research on Lead Development Program Candidate, a First-in-Class PIP4K2C Protein Degrader, at AACR 2024
From Larkspur Biosciences, Inc.
Via GlobeNewswire
Larkspur Biosciences Announces CEO Catherine Sabatos-Peyton to Participate in Upcoming Biotech Events
From Larkspur Biosciences, Inc.
Via GlobeNewswire
Larkspur Biosciences to Present New Mechanistic Data on the Role of Pin1 in Modulating the Fibroblast – Cancer Axis at SITC 2023
From Larkspur Biosciences, Inc.
Via GlobeNewswire
Larkspur Biosciences Announces First-in-Class Program Targeting Novel B Cell Checkpoint
From Larkspur Biosciences, Inc.
Via GlobeNewswire
Larkspur Biosciences to Participate in the 2023 BIO International Convention
From Larkspur Biosciences, Inc.
Via GlobeNewswire
Larkspur Biosciences Launches with $35.5 Million in Financing to Build the Next Precision Immunotherapies to Outsmart Cancer
From Larkspur Biosciences, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.